Ingrid Masson

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Performance comparison of modified ComBat for harmonization of radiomic features for multicenter studies

Ronrick Da‐ano, Ingrid Masson, François Lucia et al. · Scientific Reports · 2020 · 186 citations · Full text

External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy

François Lucia, Dimitris Visvikis, Martin Vallières et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2018 · 176 citations

Adaptive Radiotherapy, Combined Pet, External Validation +13

Pretreatment ¹⁸F-FDG PET/CT Radiomics Predict Local Recurrence in Patients Treated with Stereotactic Body Radiotherapy for Early-Stage Non–Small Cell Lung Cancer: A Multicentric Study

Gurvan Dissaux, Dimitris Visvikis, Ronrick Da‐ano et al. · Journal of Nuclear Medicine · 2019 · 161 citations · Full text